Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

PURPOSE: Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant. PATIENTS AND METHODS: Patients with newly diagnosed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cortes, Jorge E., Jones, Dan, O'Brien, Susan, Jabbour, Elias, Konopleva, Marina, Ferrajoli, Alessandra, Kadia, Tapan, Borthakur, Gautam, Stigliano, Denise, Shan, Jianqin, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815701/
https://ncbi.nlm.nih.gov/pubmed/20008621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.4896
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars